Long-term outcome for immune suppression and immune related lymphoproliferative disorder: Prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 842-848

  Taj, Mary M ^a   Hadzic, Nedim ^b   Height, Susan E ^b   Wotherspoon, Andrew ^a   Burke, Margaret ^c   Hobson, Rachel ^d   Viskaduraki, Maria ^e   Pinkerton, C Ross ^f  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c HAREFIELD HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

chemotherapeutic approaches; Lymphoma and Hodgkin disease; prognostication

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER REGISTRY; CARDIAC GRAFT REJECTION; CHILD; CHILDHOOD MORTALITY; CROHN DISEASE; DRUG DOSE REDUCTION; EPSTEIN BARR VIRUS INFECTION; EVENT FREE SURVIVAL; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE TRANSPLANTATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SURVIVAL TIME; UNITED KINGDOM;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; CHILD, PRESCHOOL; FOLLOW-UP STUDIES; GREAT BRITAIN; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; INFANT; LYMPHATIC DISEASES; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; REGISTRIES; TREATMENT OUTCOME;

EID: 84859991384     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.634045     Document Type: Article

References (38)

1. Swerdlow SH. Post-transplant lymphoproliferative disorders: a working classifi cation. Curr Diagn Pathol 1997;4:28-35.
2. Swerdlow SH. Classifi cation of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol 1997;14: 2-7. (Pubitemid 27078880)
3. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997;14:8-14. (Pubitemid 27078881)
4. Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005; 23:6481-6488. (Pubitemid 46190239)
5. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001;71:1076-1088. (Pubitemid 32448822)
6. Hayashi RJ, Kraus MD, Patel AL, et al. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol 2001;23:14-18. (Pubitemid 32124979)
7. Taj MM, Messahel B, Mycroft J, et al. Effi cacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. Br J Haematol 2008;140:191-196. (Pubitemid 350265042)
8. Ifthikharuddin JJ, Mieles LA, Rosenblatt JD, et al. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab. Am J Hematol 2000;65:171-173.
9. Messahel B, Taj MM, Hobson R, et al. Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review. Leuk Lymphoma 2006;47:2584-2589. (Pubitemid 44932648)
10. Ghobrial IM, Habermann TM, Ristow KM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005;46:191-196. (Pubitemid 40185948)
11. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006;6:569-576. (Pubitemid 43382145)
12. Pinkerton CR, Hann I, Weston CL, et al. Immunodefi ciencyrelated lymphoproliferative disorders: prospective data from the United Kingdom Children's Cancer Study Group Registry. Br J Haematol 2002;118:456-461. (Pubitemid 34994649)
13. Malatack JF, Gartner JC Jr, Urbach AH, et al. Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern. J Pediatr 1991;118:667-675.
14. Gerrard M, CCLG National guidelines for the management of Burkitt/ Burkitt like lymphoma and B Large Non Hodgkins Lymphoma.2003. www.cclg.org.uk
15. Stata Statistical Software: Release 10. College Station, TX: StataCorp; 2007.
16. Maecker B, Jack T, Zimmermann M, et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007;25:4902-4908. (Pubitemid 350220420)
17. Choquet S, Leblond V, Herbrecht R, et al. Effi cacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107:3053-3057.
18. Maloney DG. Mechanism of action of rituximab. Anticancer Drugs 2001;12(Suppl. 2):S1-S4. (Pubitemid 32641719)
19. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001;7:709-723. (Pubitemid 32707998)
20. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629-3636. (Pubitemid 46842700)
21. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520-535. (Pubitemid 41295078)
22. Orjuela M, Gross TG, Cheung YK, et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003;9:3945S - 3952S. (Pubitemid 37169201)
23. Gross TG, Orjuela M, Hayashi RJ, et al. Preliminary results of low dose chemotherapy and rituximab for pediatric, refractory post transplant lymphoproliferative disease (PTLD) following solid organ transplantation (SOT): a Children's Oncology Group phase II study. Hematol Meet Rep 2009;3:74.
24. Smets F, Vajro P, Cornu G, et al. Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation 2000;69:982-984. (Pubitemid 30174132)
25. Windebank K, Walwyn T, Kirk R, et al. Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/ lymphoma treated with low intensity chemotherapy and rituximab. Pediatr Blood Cancer 2009;53:392-396.
26. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 2006;367:233-239. (Pubitemid 43107668)
27. Manlhiot C, Pollock-Barziv SM, Holmes C, et al. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. J Heart Lung Transplant 2010;29:648-657.
28. Ocheni S, Kroeger N, Zabelina T, et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008;42:181-186.
29. Gerritsen EJ, Stam ED, Hermans J, et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLAidentical BMT in children. Bone Marrow Transplant 1996;18:377-382. (Pubitemid 26283689)
30. Jeon TY, Kim JH, Eo H, et al. Posttransplantation lymphoproliferative disorder in children: manifestations in hematopoietic cell recipients in comparison with liver recipients. Radiology 2010;257:490-497.
31. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999;94:2208-2216. (Pubitemid 29467666)
32. van Esser JW, van der HB, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001;98:972-978.
33. Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004;103:3979-3981. (Pubitemid 38596322)
34. Faraci M, Caviglia I, Morreale G, et al. Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children. Bone Marrow Transplant 2010;45:1052-1055.
35. Annels NE, Kalpoe JS, Bredius RG, et al. Management of Epstein- Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specifi c T cell reconstitution. Clin Infect Dis 2006;42:1743-1748. (Pubitemid 43839440)
36. Meij P, van Esser JW, Niesters HG, et al. Impaired recovery of Epstein-Barr virus (EBV)-specifi c CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003;101:4290-4297. (Pubitemid 36857791)
37. Clave E, Agbalika F, Bajzik V, et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specifi c T-cell reconstitution and rituximab therapy. Transplantation 2004;77:76-84. (Pubitemid 38116876)
38. van Esser JW, Niesters HG, van der HB, et al. Prevention of Epstein- Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364-4369. (Pubitemid 34627202)